On January 10, 2025, Quanterix Corporation announced a definitive merger agreement to acquire Akoya Biosciences in an all-stock transaction. This combination aims to create the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers.
Under the terms, Akoya shareholders will receive 0.318 shares of Quanterix common stock for each Akoya share, representing a 19% premium to Akoya’s unaffected stock price on November 14, 2024. Following the close, Quanterix shareholders are expected to own approximately 70% of the combined company.
The transaction is anticipated to close in the second quarter of 2025, subject to shareholder and regulatory approvals. Quanterix expects to generate approximately $40 million of annual cost synergies by the end of 2026 and projects a path to positive free cash flow generation in 2026, with a combined cash position of approximately $175 million at closing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.